TY - JOUR
T1 - Unmasking catamenial hemoptysis in the era of CFTR modulator therapy
AU - Montemayor, Kristina
AU - Claudio, Abigail T.
AU - Carson, Sara
AU - Lechtzin, Noah
AU - Christianson, Mindy S.
AU - West, Natalie E.
N1 - Publisher Copyright:
© 2020
PY - 2020/7
Y1 - 2020/7
N2 - Background: Thoracic endometriosis syndrome (TES) is a rare condition that occurs in women when endometriosis implants into the thoracic cavity. Catamenial hemoptysis, the occurrence of hemoptysis with menstruation, is a recognized clinical manifestation of TES commonly treated with hormonal therapy. Case summary: We present the first documented case describing the recrudescence of catamenial hemoptysis in the setting of Lumacaftor/Ivacaftor administration in a 25-year-old woman with cystic fibrosis (CF). Discussion: We review the literature on TES, pharmacologic management, and reported cystic fibrosis transmembrane conductance regulator (CFTR) modulator drug interactions. We propose that our patient's recrudescence of catamenial hemoptysis was secondary to a drug-drug interaction between Lumacaftor/Ivacaftor and oral contraceptive therapy. Conclusion: Our case suggests that women with CF who have catamenial hemoptysis and a genetic mutation approved for Tezacaftor/Ivacaftor or Elexacaftor/Tezacaftor/Ivacaftor can be managed effectively with either CFTR modulator and hormonal contraceptive therapy.
AB - Background: Thoracic endometriosis syndrome (TES) is a rare condition that occurs in women when endometriosis implants into the thoracic cavity. Catamenial hemoptysis, the occurrence of hemoptysis with menstruation, is a recognized clinical manifestation of TES commonly treated with hormonal therapy. Case summary: We present the first documented case describing the recrudescence of catamenial hemoptysis in the setting of Lumacaftor/Ivacaftor administration in a 25-year-old woman with cystic fibrosis (CF). Discussion: We review the literature on TES, pharmacologic management, and reported cystic fibrosis transmembrane conductance regulator (CFTR) modulator drug interactions. We propose that our patient's recrudescence of catamenial hemoptysis was secondary to a drug-drug interaction between Lumacaftor/Ivacaftor and oral contraceptive therapy. Conclusion: Our case suggests that women with CF who have catamenial hemoptysis and a genetic mutation approved for Tezacaftor/Ivacaftor or Elexacaftor/Tezacaftor/Ivacaftor can be managed effectively with either CFTR modulator and hormonal contraceptive therapy.
KW - CFTR modulators
KW - Hemoptysis
KW - Women's health
UR - http://www.scopus.com/inward/record.url?scp=85078338699&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078338699&partnerID=8YFLogxK
U2 - 10.1016/j.jcf.2020.01.005
DO - 10.1016/j.jcf.2020.01.005
M3 - Article
C2 - 31987762
AN - SCOPUS:85078338699
SN - 1569-1993
VL - 19
SP - e25-e27
JO - Journal of Cystic Fibrosis
JF - Journal of Cystic Fibrosis
IS - 4
ER -